CBS

Chr 21AR

cystathionine beta-synthase

Also known as: HIP4

The protein encoded by this gene acts as a homotetramer to catalyze the conversion of homocysteine to cystathionine, the first step in the transsulfuration pathway. The encoded protein is allosterically activated by adenosyl-methionine and uses pyridoxal phosphate as a cofactor. Defects in this gene can cause cystathionine beta-synthase deficiency (CBSD), which can lead to homocystinuria. This gene is a major contributor to cellular hydrogen sulfide production. Multiple alternatively spliced transcript variants have been found for this gene. [provided by RefSeq, Feb 2016]

GeneReviewsOMIMResearchGenerating clinical summary…
LOFmechanismARLOEUF 0.732 OMIM phenotypes
Clinical SummaryCBS
🧬
Gene-Disease Validity (ClinGen)
classic homocystinuria · ARDefinitive

Definitive — sufficient evidence for diagnostic panels

Population Constraint (gnomAD)
Low constraint (pLI 0.00) — loss-of-function variants are relatively tolerated in the population.
📋
ClinVar Variants
169 unique Pathogenic / Likely Pathogenic· 188 VUS of 874 total submissions
💊
Clinical Trials
8 active or recruiting trials — potential therapeutic options may be available
📖
GeneReview available — CBS
Authoritative clinical overview · Recommended first read
Open GeneReview ↗

Population Genetics & Constraint

gnomAD v4 — loss-of-function & missense intolerance

Tolerant — LoF & missense variants common in population
LoF Constraint?
0.73LOEUF
pLI 0.000
Z-score 2.64
OE 0.45 (0.290.73)
Tolerant

Typical tolerance to LoF variation

Missense Constraint?
0.83Z-score
OE missense 0.87 (0.790.96)
301 obs / 344.4 exp
Tolerant

Mild missense constraint

Observed / Expected Ratios?
LoF OE?0.45 (0.290.73)
00.351.4
Missense OE?0.87 (0.790.96)
00.61.4
Synonymous OE?1.11
01.21.6
LoF obs/exp: 12 / 26.7Missense obs/exp: 301 / 344.4Syn Z: -1.11
Curated Mechanism (G2P)Gene2Phenotype (DDG2P) ↗
definitiveCBS-related homocystinuria due to cystathionine beta-synthase deficiencyLOFAR

This gene — mechanism propensity

Predictions shown for reference only — model trained on dominant genes, not applicable to AR conditions.

DN
0.75top 25%
GOF
0.6542th %ile
LOF
0.2582th %ile

The Badonyi & Marsh prediction model was trained exclusively on dominant disease genes. Predictions are not reliable for genes with autosomal recessive inheritance and are shown at reduced opacity for reference only.

Predictions from Badonyi M, Marsh JA. PLoS ONE. 2024;19(8):e0307312.

ClinVar Variant Classifications

874 submitted variants in ClinVar

Classification Summary

Pathogenic47
Likely Pathogenic122
VUS188
Likely Benign453
Benign24
Conflicting23
47
Pathogenic
122
Likely Pathogenic
188
VUS
453
Likely Benign
24
Benign
23
Conflicting

Curated Variants Distribution

Classified variants from ClinVar · 5 ACMG categories

ClassificationLoFMissense + InframeNon-codingSynonymousTotal
Pathogenic
34
5
8
0
47
Likely Pathogenic
64
56
2
0
122
VUS
3
155
24
6
188
Likely Benign
0
2
222
229
453
Benign
1
0
23
0
24
Conflicting
23
Total102218279235857

LoF = frameshift, stop gained/lost, canonical splice · Counts from ClinVar esearch · Updated hourly

View in ClinVar →

21 pathogenic / likely-pathogenic (of 26) ClinVar copy-number / structural variants overlap CBS — these span large chromosomal regions, not the gene specifically, and are excluded from the counts above. Explore in CNV tools →

Protein Context — Lollipop Plot

CBS · protein map & ClinVar variants

Showing all ClinVar variants across the protein. Search a specific variant to highlight its position.

Clinical Trials

Active and recruiting trials from ClinicalTrials.gov

Progressive Supranuclear PalsyMultiple System AtrophyCorticobasal Syndrome

The NADAPT Study: a Randomized Double-blind Trial of NAD Replenishment Therapy for Atypical Parkinsonism

RECRUITING
NCT06162013Phase PHASE2Haukeland University HospitalStarted 2024-03-05
Nicotinamide RibosidePlacebo
PSPPSP - Progressive Supranuclear PalsyCorticobasal Syndrome

The CurePSP Genetics Program

RECRUITING
NCT06647641Massachusetts General HospitalStarted 2024-10-08
Whole genome sequencing will be performed at the NIH
ALS

Amyotrophic Lateral Sclerosis (ALS) Families Project

RECRUITING
NCT03865420Columbia UniversityStarted 2018-09-11
Obesity and OverweightPre-diabeticType 2 Diabetes Mellitus (T2DM)

Targeted Precision Nutrition Strategy To Prevent Chronic Metabolic Diseases

RECRUITING
NCT06923644Phase NAMaastricht University Medical CenterStarted 2025-04-23
Optimal Metabotype-specific dietSub-optimal diet
ALSFTDALS (Amyotrophic Lateral Sclerosis)Frontal Temporal Dementia (FTD)

Effects of Probiotics in Amyotrophic Lateral Sclerosis-Frontotemporal Dementia Spectrum Disorder (ALS-FTDSD) Patients

RECRUITING
NCT06051123Phase NACentre hospitalier de l'Université de Montréal (CHUM)Started 2024-01-01
ProbioticPlacebo
Amyotrophic Lateral Sclerosis

Personalized Antisense Oligonucleotide Therapy for A Single Patient With CHCHD10 ALS (nL18576)

NOT YET RECRUITING
NCT07423494Phase PHASE1, PHASE2n-Lorem FoundationStarted 2026-03
nL-CHCHD-001
SepsisARDSCritical Illness

Early Severe Illness TrAnslational BioLogy InformaticS in Humans

RECRUITING
NCT05591924London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph'sStarted 2024-04-26
PhelebotomyBroncheoalveolar LavageTracheal Aspirate
Neurodegenerative DiseaseBehavioral Variant Frontotemporal Dementia (bvFTD)Primary Progressive Aphasia(PPA)

Tracking and Predicting How Brain Damage Spreads in Neurodegenerative Diseases

ENROLLING BY INVITATION
NCT07567664Phase NAIRCCS San RaffaeleStarted 2017-06-01
3 Tesla MRI without contrast mediumBlood sample for genetic analysisCerebrospinal fluid sampling (CSF)